EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits

E Hoch, N D Volkow, C M Friemel, V Lorenzetti, T P Freeman, W Hall

European Archives of Psychiatry and Clinical Neuroscience · 2025-03 · 275 (2) · 281-292

DOI: 10.1007/s00406-024-01880-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, online erschienen am 19.09.2024. Verfasst von E Hoch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany. Eva.Hoch@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Medical Marijuana, Cannabinoids, Marijuana Abuse, Cannabis. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The legalization of cannabis for medical and recreational purposes has progressed internationally. Cannabis and cannabinoids are advocated for a plethora of medical indications. An increasing number of medical and nonmedical users regularly consume large doses of delta-9-Tetrahydrocannabinol (THC), the main active component of cannabis. Aim: to summarize the evidence on (1) risks of recreational cannabis use and (2) effectiveness and safety of medicinal cannabis. Findings on recreational use: Cannabis is mostly used to experience its acute rewarding effects. Regular use of high THC products can produce addiction (cannabis use disorder or CUD). Acute consumption of high THC doses (including unintentionally) can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor vehicle accidents. Chronic patterns of cannabis use have been associated with multiple adverse outcomes that are of particular concern among adolescents and young adults, such as, disrupted learning, impaired cognitive performance, reduced educational attainment and an increased risk of CUD, psychosis/schizophrenia, mood and anxiety disorders and suicidal behaviors. There is debate about the extent to which cannabis use is a cause of these adverse outcomes. Physical health risks (e.g., respiratory and cardiovascular, prematurity and restricted fetal growth, hyperemesis syndrome among others) have also been linked with repeated consumption of cannabis with a high THC content. Findings on medical cannabis use: Herbal cannabis, medicines from extracted or synthetized cannabinoids—often used as adjuvants to standard medicines—may produce small to modest benefits. This is primarily the case in treating chronic pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and refractory epilepsy (in the case of cannabidiol, CBD). The evidence is inconclusive on their value in treating mental disorders and other medical conditions. Safety: Cannabis-based medicine is generally well tolerated. There is a risk of mild to moderate adverse effects and CUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaCannabinoidsMarijuana AbuseCannabisHumansDronabinol

Stichwörter der Autor:innen

Cannabinoids*/therapeutic useCannabis*/adverse effectsHumansMarijuana abuseMedical Marijuana*Public health

Substanzen

Medical MarijuanaCannabinoidsDronabinol

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany. Eva.Hoch@med.uni-muenchen.de.
  • IFT Institut für Therapieforschung, Centre for Mental Health and Addiction Research, Munich, Germany. Eva.Hoch@med.uni-muenchen.de.
  • Department Clinical Psychology and Psychotherapy, Charlotte Fresenius University, Munich, Germany. Eva.Hoch@med.uni-muenchen.de.
  • National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.
  • IFT Institut für Therapieforschung, Centre for Mental Health and Addiction Research, Munich, Germany.
  • Neuroscience of Addiction and Mental Health Program, School of Behavioural and Health Sciences, Faculty of Health Science, Australian Catholic University, Melbourne, Victoria, 3065, Australia.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience, 275(2), 281-292. https://doi.org/10.1007/s00406-024-01880-2

Vancouver

Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. 2025;275(2):281-292. doi:10.1007/s00406-024-01880-2

BibTeX
@article{Hoch2025,
  author = {Hoch, E and Volkow, N D and Friemel, C M and Lorenzetti, V and Freeman, T P and Hall, W},
  title = {Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  volume = {275},
  number = {2},
  pages = {281--292},
  doi = {10.1007/s00406-024-01880-2}
}
Kostenlos starten →